Nice find BFW. I will add it to the link library. A lot of good info in there. My favorite quote is:

"Competitor molecules "hit everything," McCaffrey explained. "We have drugs that are very good that hit everything, as well, but we also have drugs in the platform that can be specific for any one of the 12 domains.""

That is good to hear. My interpretation of this comment is that they have compounds that are not only specific to the first or the second bromodomain, but they can also target the first or the second bromodomain in a particular BET protein (such as BRD2, BRD3, BRD4, BRDT) or a subset of BRDs. Very exciting. This was the biggest criticism that I heard of the therapeutic potential of BET inhibitors at the Epigenetics: Cancer and Beyond NYAS webcast. So although Zenith is starting with a pan-inhibitor that will hit both bromodomains in most if not all BET proteins, they must have a lot in their pre-clinical pipeline.

BearDownAZ